7 Mar 2016 Additional N-glycosylation in the N-terminal region of recombinant human alpha-1 antitrypsin enhances the circulatory half-life in Sprague-Dawley rats.
24 AUG 2016 Human Phase1 Clinical Data of ALT-P1 (hGH-NexP) by Healthy Korean Males
Background: ALT-P1 (CJ-40002) is a long-acting recombinant growth hormone (GH) fused with NexP, which is a long-acting carrier developed by Alteogen Inc. NexP is a protein engineered recombinant alpha
2 MAR 2016 | Alteogen set to start phase I testing for Herceptin biosimilar
Health Canada approved a phase I trial for Alteogen’s ALT02, a biosimilar version of trastuzumab
12 OCT 2015 | Alteogen inks deal with 3Sbio for ADC targeting HER2
A novel ADC targeting HER2 pathways based on Alteogen's NexMab ADC technology.
13 JUL 2015 | The patent for long-acting recombinant Alpha-1 Antitrypsin (A1AT)
ALTEOGEN succeeded in registering the patent for long-acting recombinant Alpha-1 Antitrypsin (A1AT) in US.